Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease
NCT ID: NCT05067595
Last Updated: 2025-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
72 participants
INTERVENTIONAL
2025-01-24
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Fecal Microbiota Transplantation for Slow Transit Constipation
NCT02526849
Fecal Microbiota Transplantation for Constipation
NCT03308461
Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation
NCT02291354
Effect of Fecal Microbiota Transplantation in Slow Transit Constipation
NCT02301221
Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation
NCT02676388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ARM I: Patients receive upper FMT capsules orally (PO) over 5 days or via post-pyloric or nasogastric (NG) feeding tube over 2 days.
ARM II: Patients undergo lower FMT via colonoscopy on day 0.
ARM III: Patients receive upper FMT capsules PO over 5 days or via post-pyloric or NG feeding tube over 2 days. Patients also receive fiber supplementation PO or via post-pyloric or NG feeding tube from the first day of FMT administration and up to 6 weeks post FMT.
ARM IV: Patients undergo lower FMT via colonoscopy on day 0. Patients also receive fiber supplementation PO or via post-pyloric or NG feeding tube from day 0 up to 6 weeks post FMT.
Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
After completion of study treatment, patients are followed up for 365 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (upper FMT)
Patients receive upper FMT capsules PO over 5 days or via post-pyloric or NG feeding tube over 2 days. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
Fecal Microbiota Transplantation
Given upper FMT PO or via post-pyloric or NG feeding tube
Survey Administration
Ancillary studies
Biospecimen Collection
Undergo tissue, stool, stool swabs, and blood sample collection
Arm II (Lower FMT)
Patients undergo lower FMT via colonoscopy on day 0. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
Colonoscopy
Undergo lower FMT via colonoscopy
Fecal Microbiota Transplantation
Undergo lower FMT via colonoscopy
Survey Administration
Ancillary studies
Biospecimen Collection
Undergo tissue, stool, stool swabs, and blood sample collection
Arm III (upper FMT, fiber supplementation)
Patients receive upper FMT capsules PO over 5 days or via post-pyloric or NG feeding tube over 2 days. Patients also receive fiber supplementation PO or via post-pyloric or NG feeding tube from the first day of FMT administration and up to 6 weeks post FMT. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
Fecal Microbiota Transplantation
Given upper FMT PO or via post-pyloric or NG feeding tube
Nutritional Supplementation
Given dietary fiber supplementation PO or via post-pyloric or NG feeding tube
Survey Administration
Ancillary studies
Biospecimen Collection
Undergo tissue, stool, stool swabs, and blood sample collection
Arm IV (Lower FMT, fiber supplementation)
Patients undergo lower FMT via colonoscopy on day 0. Patients also receive fiber supplementation PO or via post-pyloric or NG feeding tube from day 0 up to 6 weeks post FMT. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
Colonoscopy
Undergo lower FMT via colonoscopy
Fecal Microbiota Transplantation
Undergo lower FMT via colonoscopy
Nutritional Supplementation
Given dietary fiber supplementation PO or via post-pyloric or NG feeding tube
Survey Administration
Ancillary studies
Biospecimen Collection
Undergo tissue, stool, stool swabs, and blood sample collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colonoscopy
Undergo lower FMT via colonoscopy
Fecal Microbiota Transplantation
Given upper FMT PO or via post-pyloric or NG feeding tube
Fecal Microbiota Transplantation
Undergo lower FMT via colonoscopy
Nutritional Supplementation
Given dietary fiber supplementation PO or via post-pyloric or NG feeding tube
Survey Administration
Ancillary studies
Biospecimen Collection
Undergo tissue, stool, stool swabs, and blood sample collection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of allogeneic hematopoietic stem cell transplant in the past 365 days
* Post-engraftment, defined by time period following three consecutive days of sustained neutrophil engraftment with an absolute neutrophil count of at least 500 cells/mm\^3
* Mild to severe acute GI GvHD, at least stage 1, as measured by one of the following:
* Modified Glucksberg criteria for GI GvHD averaged over 3 consecutive days and without another explanation for diarrhea such as laxative use or infection. In patients who have already had GI biopsy, biopsy histology must be compatible with GVHD, although biopsy is not required
* Biopsy evidence of GI GVHD in the upper or lower GI tract
Exclusion Criteria
* History of bowel perforation in the last 90 days
* History of gastrointestinal resection in the last 90 days
* History of intestinal obstruction in the last 90 days
* History of diverticulitis in the last 90 days
* History of celiac disease confirmed by serologic testing or small bowel biopsy
* History of severe dietary allergy as designated by World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System grade 2 or more
* Subjects who are cytomegalovirus (CMV) seronegative at the time of enrollment as indicated by clinical testing unless the fecal microbiota transplant (FMT) donor is CMV seronegative with negative plasma polymerase chain reaction (PCR) assays for CMV.
* Known allergies to loperamide, sodium chloride, glycerol, theobroma oil, hide bovine gelatin, sodium lauryl sulfate, colorants FD\&C, titanium dioxide, polyethylene glycol, sodium sulfate, sodium bicarbonate, sodium phosphate, benzalkonium chloride, disodium EDTA or potassium chloride.
* Currently pregnant, planning to become pregnant or breastfeeding during the study period. Women of childbearing potential (those who are not post-menopausal or post-hysterectomy) must be negative for pregnancy per urine pregnancy test at enrollment
* Individuals with the ability to conceive children who are not willing to abstain from sexual activity or use an effective form of birth control during the duration of the study
* Unwilling or unable to participate in study procedures including oral intake of FMT, colonoscopy, fiber supplementation, collection of stool samples and completion study surveys
* Cannot reasonably and safely participate in the study in the opinion of the investigators
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Fredricks
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-07698
Identifier Type: REGISTRY
Identifier Source: secondary_id
10276
Identifier Type: OTHER
Identifier Source: secondary_id
RG1006202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.